Literature DB >> 22533665

The association of leptin and C-reactive protein with the cardiovascular risk factors and metabolic syndrome score in Taiwanese adults.

Feng-Hsiang Chiu1, Chung Hsun Chuang, Wen-Cheng Li, Yi-Ming Weng, Wen-Chih Fann, Hsiang-Yun Lo, Cheng Sun, Shih-Hao Wang.   

Abstract

BACKGROUND: Serum C-reactive protein (CRP) and leptin levels have been independently associated with the cardiovascular risk factors. The aim of the present study was to determine if their serum levels were associated with cardiovascular risk factors or metabolic syndrome as well as their correlation in the Taiwanese population.
METHODS: This retrospective study included 999 subjects (> 18 y), who underwent a physical examination in Chang-Gung Memorial Hospital-Linkou and Chiayi in Taiwan. The associations between CRP and/or leptin levels and cardiovascular risk factors and metabolic syndrome were determined using independent two sample t-tests to detect gender differences and chi-square tests to evaluate differences in frequencies. To compare the means of the variables measured among the four groups (high and low leptin and high and low CRP), analysis of variance (ANOVA) was used.
RESULTS: Both CRP and leptin levels were independently associated with several cardiovascular risk factors, including diabetes, hypercholesterolemia and metabolic syndrome in both men and women (P < 0.05). In addition, a positive correlation between leptin and CRP levels was observed in both genders. Both high-CRP and high-leptin were associated with high blood glucose, waist circumference and serum triglyceride. Whereas increased metabolic syndrome incidence was observed in males with elevated leptin regardless of CRP levels, females with elevated CRP or leptin had increased incidence of metabolic syndrome.
CONCLUSION: Both leptin and CRP levels were associated with cardiovascular risk factors as well as metabolic syndrome score in both men and women although gender-specific differences were observed. Thus, CRP and leptin may represent useful biomarkers for predicting the onset of cardiovascular disease or metabolic syndrome in Taiwanese adults. TRIAL REGISTRATION: IRB/CGMH 100-3514B.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22533665      PMCID: PMC3471043          DOI: 10.1186/1475-2840-11-40

Source DB:  PubMed          Journal:  Cardiovasc Diabetol        ISSN: 1475-2840            Impact factor:   9.951


Background

Because a combination of several cardiovascular and diabetes risk factors comprise metabolic syndrome, it has been postulated that factors involved in both diseases may interact. Two such factors include leptin and C-reactive protein (CRP), and both are associated with indices of obesity and cardiovascular disease. CRP is an inflammatory marker of cardiovascular disease [1]; elevated levels are associated with increased risk of future coronary heart disease [2-4]. Obesity is one of the strongest determinants of CRP levels [5]. Furthermore, CRP has been related to metabolic syndrome in several studies [2,6], and its production is influenced by leptin [7]. Leptin is expressed by adipose tissue [8], regulating appetite and energy expenditure as well as insulin homeostasis [9]. Leptin levels predict metabolic syndrome development independent of obesity [10]. In men [11] and patients with type 2 diabetes [12], leptin levels were associated with cardiovascular disease. This association may be through inflammatory mechanisms since leptin and CRP levels have been correlated in a variety of patient populations [13-17]. In addition to cardiovascular disease, CRP and leptin levels are predictive of metabolic syndrome development. In middle-aged subjects, high leptin in men and high CRP in women were significant predictors of metabolic syndrome; those with elevations in both markers had the highest risk of developing metabolic syndrome [18]. However, the effects of CRP and leptin levels in a Taiwanese population have yet to be determined. The objective of the present study was to determine if CRP and leptin levels are associated with cardiovascular disease risk factors as well as metabolic syndrome score in healthy Taiwanese adults. In addition, the possible correlation between CRP and leptin levels was also explored in this population. CRP and leptin may represent useful biomarkers for predicting the onset of cardiovascular disease or metabolic syndrome in Taiwanese adults.

Methods

Study population

In 2010, 1025 subjects (> 18 y), who had undergone a routine physical examination in Chang-Gung Memorial Hospital-Linkou (North Taiwan) and Chiayi (South Taiwan), were selected to participate in this retrospective study. Participants were included if they had undergone a physical exam in which the following parameters were assessed: weight, height, blood pressure, waist circumference, total cholesterol, triglyceride, fasting glucose, high density lipoprotein- cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), CRP, and leptin. Patients were exclude if they had not fasted for 12 h, were pregnant, or had a history of cardiovascular disease (e.g., myocardial infarction or stroke),chronic inflammatory disease (e.g., chronic rheumatoid arthritis, hepatitis, and cancer), or endocrine disease (e.g., hyperthyroidism or hypothyroidism). The study was approved by the Institute Reviewing Board of Chang Gung Memorial Hospital. As shown in Table 1, after 26 participants were excluded, a total of 999 participants were analyzed, including 720 males (35.79 ± 7.94 y) and 279 females (38.60 ± 12.80 y).
Table 1

Subject characteristics by gender

 Men (n = 720)Women (n = 279)P-value
Age (y)1
35.79 ± 7.94
38.60 ± 12.80
0.001
MS, n (%)2
61 (8.5)
59 (21.1)
<0.001
Diabetes mellitus, n (%)2
19 (2.6)
8 (2.9)
0.842
BMI (kg/m2)1
24.70 ± 3.43
21.90 ± 3.19
<0.001
Waist circumference (cm)1
81.76 ± 10.35
82.51 ± 9.67
0.294
Systolic BP (mm Hg)1
125.14 ± 13.27
113.08 ± 15.12
<0.001
Diastolic BP (mm Hg)1
78.69 ± 9.96
70.56 ± 9.83
<0.001
Fasting blood glucose (mg/dL)1
88.79 ± 12.69
90.09 ± 21.21
0.233
Total cholesterol (mg/dL)1
183.85 ± 32.84
184.53 ± 30.42
0.335
LDL cholesterol (mg/dL)3
119 (99, 139)
120 (99, 141)
0.855
HDL cholesterol (mg/dL)3
50 (43, 59)
50 (42, 59)
0.959
Triglycerides (mg/dL)3
91 (65, 128)
96 (68, 142)
0.119
Uric acid (mg/dL)1
6.28 ± 1.51
6.43 ± 1.50
0.163
Leptin (ng/mL)3
4.99 (3.03, 8.18)
5.51 (3.21, 9.56)
0.089
CRP (μg/mL)30.77 (0.42, 1.72)0.85 (0.44, 1.79)0.407

P-values are based on 1independent two sample t-test, 2Chi-square, or 3Mann-Whitney U test. Data are displayed as 1 mean ± SD, 2number (percentage), or 3 median (interquartile). Abbreviations: MS, metabolic syndrome; BMI, body mass index; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; and CRP, C-reactive protein.

Subject characteristics by gender P-values are based on 1independent two sample t-test, 2Chi-square, or 3Mann-Whitney U test. Data are displayed as 1 mean ± SD, 2number (percentage), or 3 median (interquartile). Abbreviations: MS, metabolic syndrome; BMI, body mass index; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; and CRP, C-reactive protein. Participants were interviewed by trained nurses. Information regarding demographic (e.g., age, gender, etc.) and life style characteristics (e.g., history of smoking, drinking, etc.), history of illness and medication use, and physiological status (e.g., pregnancy, fasting time, etc.) was collected (Table 1).

Blood pressure, BMI, and waist circumference measurements

Systolic and diastolic blood pressures were measured with a random zero sphygmomanometer while patients were in sitting position after a 5-min period of rest, according to the American Heart Association and Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommendations [19], and the average of up to three independent measurements was used. To determine body mass index (BMI), the height and weight of each patient were measured using an automatic scale. BMI was calculated as weight (kg) divided by the height squared (m2). Waist circumference was determined with the patient standing with their feet 25 to 30 cm apart. It was measured midway between the iliac crest and the lower margin of the 12th rib.

Laboratory measurements

After a 12-h fast, venous blood samples were obtained between 5:30 to 11:00 a.m. and stored at 4°C. Total cholesterol, HDL-C, triglyceride (TG), fasting blood glucose (FBG), LDL-C, and leptin levels were determined for each participant. CRP was determined using a high sensitivity CRP assay.

Cardiometabolic risk factor variables

Individuals were considered hypertensive if they were taking antihypertensive medications, self-reported a diagnosis of hypertension, if their systolic pressure was > 140 mmHg or diastolic pressure was > 90 mmHg, or if a combination of these features was recorded [20]. Participants were considered to have diabetes if they reported a current usage of antidiabetic medications, reported a previous diagnosis of diabetes, or had a FBG > 126 mg/dL [21]. A patient was considered to have dyslipidemia if they had the following: plasma TC ≥ 240 mg/dL and/or use of medications to lower blood cholesterol, TG ≥ 200 mg/dL, HDL-C < 40 mg/dL, and LDL-C ≥ 160 mg/dL and/or use of medications to lower LDL-C [22]. Regarding tobacco and alcohol use, those who had smoked ≥ 100 cigarettes in their lifetime were considered to have “ever smoked”. Alcohol use was defined as any alcohol use within the last year. Leptin concentrations >4.99 ng/mL in men and >5.51 ng/mL in women were defined as “high”. CRP values >3 μg/mL in both men and women were defined as “high”.

Definition of metabolic syndrome

A participant was diagnosed with metabolic syndrome if they presented with at least three of the following five factors: 1) high blood pressure (systolic blood pressure ≥ 130 mmHg and/or diastolic pressure ≥ 85 mmHg, under treatment, or current hypertension diagnosis); 2) high serum triglyceride (≥ 150 mg/dL or under treatment); 3) decreased HDL-C (< 40 mg/dL for males and < 50 mg/dL for females or under treatment); 4) hyperglycemia (FBG ≥ 100 mg/dL, under treatment, or diagnosis with diabetes mellitus); and 5) abdominal obesity [23]. Modified waist circumference cutoffs for Asian populations were used, which consisted of a waist circumference ≥ 90 cm for men and ≥ 80 cm for women [24].

Statistical analysis

To compare the variables by gender or presence, independent two sample t-tests were used. For evaluating differences in frequencies, the chi-square test was used. Because leptin and CRP levels were not normally distributed, Mann–Whitney U tests were used. To compare the means of the variables among the four groups (high and low leptin and high and low CRP), analysis of variance (ANOVA) was used. If the data was not normally distributed, a Kruskal-Wallis test was performed. When a significant difference between groups was apparent, multiple comparisons were performed using the Bonferroni procedure with type-I error adjustment. The correlation between leptin and CRP was determined using Spearman’s correlation coefficient. The partial correlations between metabolic syndrome components and CRP and leptin were calculated while controlling for age, or age and BMI. All statistical assessments were two-sided and considered significant when P < 0.05. Statistical analyses were performed using SPSS 15.0 statistical software (SPSS Inc, Chicago, IL).

Results

Participant characteristics

As shown in Table 1, the characteristics of the study subjects were compared by gender, and significant differences were observed. Specifically, women were significantly older and had a significantly lower BMI and systolic and diastolic blood pressures as compared to men (P ≤ 0.001). In addition, the prevalence of metabolic syndrome was significantly lower in male participants (8.5 vs. 21.1%, P < 0.001). No gender differences in leptin or CRP levels were observed.

Associations between leptin and CRP levels with cardiovascular risk factors

Serum leptin levels were evaluated to determine if they were associated with cardiovascular risk factors in Taiwanese adults as previously reported in men [11] and those with type 2 diabetes [12]. In both men and women, diabetes, hypercholesterolemia and metabolic syndrome were significantly associated with elevated leptin levels (Table 2). In addition, gender differences were observed; men who were ever tobacco users, as well as those with hypertriglyceridemia and high LDL-C had significantly higher leptin levels. No such associations were detected in women.
Table 2

Leptin levels in patients with and without cardiovascular disease risk factors

 Men (n = 720)Women (n = 279)
 
Absent
Present
P-value
Absent
Present
P-value
Diabetes
4.96 (2.97, 8.02)
6.97 (4.90, 8.56)
0.044
5.50 (3.14, 9.40)
8.65 (4.79, 12.35)
0.049
Hypercholesterolemia
4.94 (2.97, 7.85)
8.02 (4.56, 11.50)
0.003
5.43 (3.14, 9.40)
8.05 (5.67, 13.95)
0.039
Hypertriglyceridemia
4.91 (2.94, 7.89)
7.18 (4.44, 10.30)
0.002
5.39 (3.12, 9.22)
6.90 (4.90, 10.75)
0.054
High LDL cholesterol
4.92 (2.94, 7.85)
6.36 (3.73, 10.20)
0.013
5.43 (3.17, 9.87)
6.15 (4.45, 9.13)
0.561
Low HDL cholesterol
4.95 (2.94, 8.32)
5.04 (3.68, 7.43)
0.610
5.51 (3.12, 9.96)
5.51 (3.32, 9.13)
0.698
Hypertension
4.94 (2.97, 8.20)
5.51 (3.11, 7.93)
0.538
5.40 (3.12, 9.36)
7.67 (4.35, 11.20)
0.087
MS
4.78 (2.90, 7.73)
7.26 (4.98, 9.52)
<0.001
5.20 (2.94, 9.74)
6.63 (4.83, 9.40)
0.010
Ever smoked
4.82 (2.90, 7.60)
5.53 (3.35, 9.34)
0.030
5.51 (3.17, 9.56)
5.71 (4.57, 6.72)
0.829
Alcohol use4.63 (2.89, 7.54)5.25 (3.28, 8.57)0.0575.53 (3.32, 9.72)5.40 (2.89, 9.40)0.548

P-values are based on Mann–Whitney U test.

Data are displayed as median (interquartile).

Abbreviations: LDL, low density lipoprotein; HDL, high density lipoprotein; and MS, metabolic syndrome.

Leptin levels in patients with and without cardiovascular disease risk factors P-values are based on Mann–Whitney U test. Data are displayed as median (interquartile). Abbreviations: LDL, low density lipoprotein; HDL, high density lipoprotein; and MS, metabolic syndrome. In both genders, those with diabetes, hypercholesterolemia, hypertriglyceridemia, low HDL-C, and metabolic syndrome all had significantly higher CRP levels (Table 3). High LDL-C was associated with high CRP levels in men only. In addition, a significantly positive correlation between leptin and CRP levels was observed in both genders (P < 0.001, Figure 1).
Table 3

CRP levels in patients with and without cardiovascular disease risk factors

 Men (n = 720)Women (n = 279)
 
Absent
Present
P-value
Absent
Present
P-value
Diabetes
0.76 (0.42, 1.67)
1.70 (0.55, 2.99)
0.044
0.82(0.43, 1.62)
2.42 (1.81, 4.06)
0.001
Hypercholesterolemia
0.75 (0.41, 1.67)
1.41 (0.81, 2.29)
0.002
0.82 (0.43, 1.64)
1.79 (1.15, 2.96)
0.013
Hypertriglyceridemia
0.74 (0.40, 1.65)
1.34 (0.76, 2.47)
<0.001
0.79 (0.39, 1.62)
1.46 (0.77, 2.09)
0.013
High LDL cholesterol
0.73 (0.40, 1.65)
1.14 (0.62, 2.04)
0.001
0.84 (0.40, 1.62)
1.21 (0.52, 2.76)
0.217
Low HDL cholesterol
0.72 (0.39, 1.53)
1.41 (0.67, 2.61)
<0.001
0.73 (0.39, 1.38)
1.06 (0.53, 2.14)
0.002
Hypertension
0.77 (0.41, 1.72)
0.78 (0.47, 1.68)
0.659
0.79 (0.42, 1.57)
1.56 (0.77, 3.72)
0.012
MS
0.72 (0.40, 1.55)
1.84 (0.87, 2.77)
<0.001
0.76 (0.39, 1.55)
1.33 (0.66, 2.81)
0.001
Ever smoked
0.76 (0.43, 1.70)
0.80 (0.40, 1.72)
0.291
0.83 (0.44, 1.69)
1.09 (0.85, 3.24)
0.279
Alcohol use0.74 (0.41, 1.70)0.80 (0.44, 1.72)0.5900.79 (0.42, 1.67)1.05 (0.48, 2.00)0.239

P-values are based on Mann–Whitney U test.

Data are displayed as median (interquartile).

Abbreviations: CRP, C-reactive protein; LDL, low density lipoprotein; HDL, high density lipoprotein; and MS, metabolic syndrome.

Figure 1

The correlation between leptin and CRP. The Spearman correlation coefficient between fasting plasma leptin and CRP was determined for both male (A) and female (B) participants. *For male participants, the Spearman correlation coefficient = 0.293, P < 0.001. For female participants, spearman correlation coefficient = 0.307, P < 0.001.

CRP levels in patients with and without cardiovascular disease risk factors P-values are based on Mann–Whitney U test. Data are displayed as median (interquartile). Abbreviations: CRP, C-reactive protein; LDL, low density lipoprotein; HDL, high density lipoprotein; and MS, metabolic syndrome. The correlation between leptin and CRP. The Spearman correlation coefficient between fasting plasma leptin and CRP was determined for both male (A) and female (B) participants. *For male participants, the Spearman correlation coefficient = 0.293, P < 0.001. For female participants, spearman correlation coefficient = 0.307, P < 0.001. As shown in Table 4, male participants with high concentrations of both leptin and CRP had a significantly greater waist circumference, metabolic syndrome incidence, FBG, and triglyceride levels and lower HDL-C than individuals with low concentrations of both leptin and CRP (P < 0.017). Moreover, female participants with high concentrations of both leptin and CRP had significantly greater waist circumference, FBG, triglyceride and LDL-C levels than individuals with low leptin and CRP concentrations (P < 0.017, Table 4).
Table 4

Baseline characteristics by leptin and CRP level

 Men (n = 720)Women (n = 279)
Variable
aLow leptin, low CRP (n = 335)
Low leptin, highCRP (n = 25)
High leptin, low CRP (n = 298)
High leptin, high CRP (n = 62)
aLow leptin, low CRP (n = 123)
Low leptin, high CRP (n = 16)
High leptin, low CRP (n = 119)
High leptin, high CRP (n = 21)
Age (y)1
35.97 ± 7.76
35.76 ± 10.26
35.85 ± 8.02
34.58 ± 7.48
36.71 ± 13.65
42.56 ± 15.17
40.15 ± 11.73
37.90 ± 10.45
BMI (kg/m2)1
24.84 ± 3.55
24.22 ± 4.07
24.63 ± 3.38
24.49 ± 2.73
21.66 ± 3.13
22.03 ± 2.95
21.96 ± 3.23
22.90 ± 3.40
Waist circumference (cm)1
79.72 ± 7.90
78.17 ± 9.67
82.32 ± 11.42b
91.56 ± 10.99b
79.95 ± 7.77
84.54 ± 5.24
84.26 ± 10.62
86.04 ± 13.07b
MS, n (%)2
14 (4.2)
2 (8.0)
34 (11.4)b
11 (17.7)b
17 (13.8)
6 (37.5)b
31 (26.1)b
5 (23.8)
Ever smoked, n (%)2
98 (29.3)
7 (28.0)
101 (33.9)
24 (31.9)
4 (3.3)
1 (6.3)
3 (2.5)
2 (9.5)
Alcohol use, n (%)2
170 (50.7)
13 (52.0)
173 (58.1)
31 (50.0)
25 (20.3)
3 (18.8)
20 (16.8)
7 (33.3)
Systolic BP (mm Hg)1
124.86 ± 11.35
128.12 ± 24.54
125.89 ± 14.25
121.79 ± 11.21
111.02 ± 12.10
117.56 ± 15.60
113.81 ± 15.78
117.62 ± 23.81
Diastolic BP (mm Hg)1
78.32 ± 8.95
80.96 ± 16.48
79.27 ± 10.40
76.98 ± 9.53
69.06 ± 9.23
72.00 ± 9.65
71.32 ± 9.43
73.90 ± 14.05
Fasting blood glucose (mg/dL)1
87.66 ± 9.29
87.12 ± 6.950
88.51 ± 10.71
96.87 ± 27.80b
87.20 ± 8.06
103.13 ± 63.91b
89.25 ± 8.66
101.90 ± 44.87b
Total cholesterol (mg/dL)1
181.40 ± 29.75
172.64 ± 30.46
185.68 ± 35.19
192.79 ± 35.93
178.28 ± 27.46
189.63 ± 37.21
190.00 ± 31.80b
186.24 ± 28.59
Triglycerides (mg/dL)3
87 (64, 117)
84 (61, 99)
98 (64, 135)
125 (79, 153)b
86 (65, 125)
119 (73, 155)
101 (68, 159)
136 (83, 151)b
LDL cholesterol (mg/dL)3
118 (99, 138)
117 (99, 129)
120 (96, 139)
126 (112, 150)
113 (95, 133)
121 (110, 155)
124 (102, 144)
129 (109, 141)b
HDL cholesterol (mg/dL)351 (43, 59)46 (40, 53)51 (43, 60)45 (40, 50)b51 (44, 59)42 (38, 50)b51 (43, 61)50 (40, 55)

a The low leptin-low CRP group was considered the reference group.

b indicates a significant difference between indicated group and the reference group,

P-values are based on 1 ANOVA test, 2 Chi-square, or 3 Kruskal-Wallis test.

Data are displayed as 1 mean ± SD, 2number (percentage), or 3 median (interquartile).

Abbreviations: CRP, C-reactive protein; BMI, body mass index; MS, metabolic syndrome; BP, blood pressure; LDL, low density lipoprotein; and HDL, high density lipoprotein.

Baseline characteristics by leptin and CRP level a The low leptin-low CRP group was considered the reference group. b indicates a significant difference between indicated group and the reference group, P-values are based on 1 ANOVA test, 2 Chi-square, or 3 Kruskal-Wallis test. Data are displayed as 1 mean ± SD, 2number (percentage), or 3 median (interquartile). Abbreviations: CRP, C-reactive protein; BMI, body mass index; MS, metabolic syndrome; BP, blood pressure; LDL, low density lipoprotein; and HDL, high density lipoprotein.

Associations between leptin and CRP levels with metabolic syndrome

The associations between leptin and CRP levels with metabolic syndrome score, which is determined as the number of metabolic syndrome components described by the ATP III criteria [23], was next determined. Leptin concentrations varied in relation to the metabolic syndrome score in both genders (  2). After adjusting for age, leptin levels significantly increased with increasing metabolic syndrome score in both male and female subjects (Figure 2, left panels; P < 0.05). Upon additional adjustment for BMI, the association between elevated leptin levels with metabolic syndrome score remained in both male (P < 0.001) and female (P = 0.002) subjects (Figure 2, right panels). Similar associations were observed for CRP levels (Figure 3). After adjusting for age, CRP levels increased with increasing metabolic syndrome score in both male and female subjects (P < 0.001). Upon additional adjustment for BMI, the association of CRP with metabolic syndrome score remained significant in both male and female subjects (P < 0.001).
Figure 2

Relationship between fasting plasma leptin concentrations and metabolic syndrome score. The association between fasting plasma leptin concentration and metabolic syndrome score was determined for male (A) and female (B) participants and adjusted for either age (left panel) or age and BMI (right panel).

Figure 3

Relationship between fasting plasma CRP levels and metabolic syndrome score. The association between fasting plasma CRP level and metabolic syndrome score was determined for male (A) and female (B) participants and adjusted for either age (left panel) or age and BMI (right panel).

Relationship between fasting plasma leptin concentrations and metabolic syndrome score. The association between fasting plasma leptin concentration and metabolic syndrome score was determined for male (A) and female (B) participants and adjusted for either age (left panel) or age and BMI (right panel). Relationship between fasting plasma CRP levels and metabolic syndrome score. The association between fasting plasma CRP level and metabolic syndrome score was determined for male (A) and female (B) participants and adjusted for either age (left panel) or age and BMI (right panel).

Discussion

This is the first study to explore the possible association and interaction between leptin and CRP levels with risk factors for cardiovascular disease and metabolic syndrome in a Taiwanese population. Both leptin and CRP levels were associated with cardiovascular risk factors as well as metabolic syndrome score in both men and women as in Xu et al. [25] although gender-specific differences were observed. Specifically, significant correlations were observed between both leptin and CRP levels with diabetes, hypercholesterolemia, and metabolic syndrome; however, gender differences were identified regarding the association between these markers and the presence of individual cardiovascular disease risk factors. Furthermore, individuals with both high leptin and high CRP levels had significantly greater waist circumference, glucose levels, triglyceride levels as compared to those with low leptin and low CRP levels. Elevated leptin and low CRP levels were associated with metabolic syndrome in both men and women. Finally, a positive correlation between leptin and CRP levels was observed as compared to previous reports [17,18]. In a previous report, we observed that leptin levels were associated with cardiovascular disease risk factors [26]. In this study, further associations between leptin and CRP levels and metabolic syndrome score were detected in both male and female participants. This is different from a previous report by Ukkola et al. in which metabolic syndrome scores were associated with high leptin and high CRP in men and with high CRP only in women after stratification by BMI in a Finish population [18]. Thus, there may be population-specific differences in the correlation between BMI and leptin level, which will require further studies to elucidate. The association between leptin and metabolic syndrome is not fully understood. Leptin receptors are found on pancreatic β cells, suppressing insulin secretion [27]. In leptin resistance, glucose-stimulated insulin secretion is not suppressed by leptin, which may lead to insulin resistance [28]. Further studies are required to determine the exact role of leptin in metabolic syndrome. As previously reported in a Finnish population [17] as well as Japanese type 2 diabetic patients [13] and healthy individuals [29], an association between leptin and CRP was observed in the Taiwanese cohort analyzed in the present study. The mechanisms linking leptin with CRP are not well known. Among the proinflammatory cytokines, CRP synthesis is primarily regulated by interleukin-6 (IL-6) [30]. Proinflammatory cytokines, which include IL-6, IL-1 and tumor necrosis factor-alpha (TNF-α) are secreted not only by adipocytes but also by inflammatory cells, such as adipose-resident macrophages [31-33]. These cytokines may stimulate leptin secretion from human adipose tissue as well as hepatic CRP synthesis [34,35]. However, leptin itself can stimulate the production of various cytokines, including IL-6 [36]. Thus, IL-6 and leptin may positively regulate the other’s expression through a feedback loop. Because the leptin receptor mediates intracellular signaling with a specificity similar to IL-6-type receptors [37], leptin may regulate CRP production not only via IL-6 but also via the leptin receptor. In addition, Chen et al. [38] demonstrated that physiological concentrations of leptin can dose-dependently stimulate CRP expression in human primary hepatocytes. An alternative explanation is that obesity upregulates the production of both leptin and a cytokine regulating CRP synthesis without a causal relationship between leptin and CRP. However, further studies are necessary to determine the exact intracellular mechanisms by which leptin regulates CRP production. Furthermore, a role for CRP in the development of leptin resistance has also been suggested, but needs to be further analyzed [39,40]. In the present study, leptin and CRP levels were associated with metabolic syndrome score, indicating that high levels of these markers may be predictive of developing metabolic syndrome similarly to that shown for high baseline fasting insulin levels [41]. Further follow-up analysis will be undertaken to fully evaluate the predictive value of these markers using a prediction model as was used by Chien et al. [42]. Differences in cardiovascular risk have been observed in obese individuals with and without adipose tissue inflammation. In a recent study by Farb et al. [43], higher plasma insulin, triglyceride, glucose, blood pressure, LDL-C and high sensitivity CRP and lower HDL-C were observed in individuals with inflamed adipose. Further studies are necessary to determine if adipose inflammation alters the association of CRP and leptin with metabolic syndrome in obese individuals. Limitations of this study include its retrospective, cross-sectional nature. In addition, the data used in the present study was collected during a routine physical examine. Because examination of CRP and leptin levels was by choice, this may select for individuals concerned about weight and/or metabolic problems. Furthermore, no information regarding exercise and diet as well as hereditary disease was collected.

Conclusions

In conclusion, this study suggests that leptin and CRP are strong predictors of not only cardiovascular disease but also metabolic syndrome in Taiwanese men and women. The associations between leptin and CRP with cardiovascular disease risk factors and metabolic syndrome score may provide a tool for assessing the risk of developing these diseases although further longitudinal studies in larger patient populations are necessary to determine the predictive value of examining their levels.

Abbreviations

ANOVA: Analysis of variance; BMI: Body mass index; CRP: C-reactive protein; FBG: Fasting blood glucose; HDL-C: High density lipoprotein- cholesterol; IL-6: Interleukin-6; LDL-C: Low density lipoprotein-cholesterol; TG: Triglyceride; TNF-α: Tumor necrosis factor-alpha.

Competing interests

We declared that there is no conflict of interests in the submission and no funding support was received for the study.

Authors’ contributions

WCL and YMW contributed to Study Design; FHC, CCH, HYL, CS and SHW contributed to Conduct/data collection; WCF contributed to Data Analysis; FHC and CCH contributed to Manuscript Writing. All authors read and approved the final manuscript.
  41 in total

Review 1.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

Review 2.  Leptin resistance and obesity.

Authors:  Hiroyuki Shimizu; Shinsuke Oh-I; Shuichi Okada; Masatomo Mori
Journal:  Endocr J       Date:  2006-10-20       Impact factor: 2.349

3.  Relation of plasma leptin to C-reactive protein in older adults (from the Invecchiare nel Chianti study).

Authors:  Alessandro Ble; B Gwen Windham; Stefania Bandinelli; Dennis D Taub; Stefano Volpato; Benedetta Bartali; Russell P Tracy; Jack M Guralnik; Luigi Ferrucci
Journal:  Am J Cardiol       Date:  2005-10-01       Impact factor: 2.778

Review 4.  The role of leptin in human obesity and disease: a review of current evidence.

Authors:  C S Mantzoros
Journal:  Ann Intern Med       Date:  1999-04-20       Impact factor: 25.391

Review 5.  Clinical endocrinology of human leptin.

Authors:  L F Van Gaal; M A Wauters; I L Mertens; R V Considine; I H De Leeuw
Journal:  Int J Obes Relat Metab Disord       Date:  1999-02

6.  Leptin, triglycerides, and interleukin 6 are independently associated with C-reactive protein in Japanese type 2 diabetic patients.

Authors:  Takiko Yanagawa; Ataru Taniguchi; Mitsuo Fukushima; Yoshikatsu Nakai; Shoichiro Nagasaka; Minako Ohgushi; Kazunari Matsumoto; Akira Kuroe; Michihiro Ohya; Yutaka Seino
Journal:  Diabetes Res Clin Pract       Date:  2006-06-09       Impact factor: 5.602

7.  Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity.

Authors:  Paul W Franks; Soren Brage; Jian'an Luan; Ulf Ekelund; Mushtaquar Rahman; I Sadaf Farooqi; Ian Halsall; Stephen O'Rahilly; Nicholas J Wareham
Journal:  Obes Res       Date:  2005-08

8.  Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro.

Authors:  Maria E Trujillo; Sean Sullivan; Ingrid Harten; Stephen H Schneider; Andrew S Greenberg; Susan K Fried
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

9.  Induction of leptin resistance through direct interaction of C-reactive protein with leptin.

Authors:  Ke Chen; Fanghong Li; Ji Li; Hongbo Cai; Steven Strom; Alessandro Bisello; David E Kelley; Miriam Friedman-Einat; Gregory A Skibinski; Mark A McCrory; Alexander J Szalai; Allan Z Zhao
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

10.  Leptin and high-sensitivity C-reactive protein and their interaction in the metabolic syndrome in middle-aged subjects.

Authors:  Olavi Ukkola; Y Antero Kesäniemi
Journal:  Metabolism       Date:  2007-09       Impact factor: 8.694

View more
  19 in total

1.  Short duration of sleep is associated with hyperleptinemia in Taiwanese adults.

Authors:  Malcolm Koo; Ning-Sheng Lai; Jui-Kun Chiang
Journal:  J Clin Sleep Med       Date:  2013-10-15       Impact factor: 4.062

2.  Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects.

Authors:  Somaye Yosaee; Mahmoud Khodadost; Alireza Esteghamati; John R Speakman; Farzad Shidfar; Mahdiyeh Nasab Nazari; Vida Bitarafan; Kurosh Djafarian
Journal:  Am J Mens Health       Date:  2016-08-22

3.  Impaired Sensitivity to Thyroid Hormones Is Associated With Elevated Blood Glucose in Coronary Heart Disease.

Authors:  Lu Yu; Zhu Li; Rongrong Yang; Guangwei Pan; Qi Cheng; Yuanyuan He; Yijia Liu; Fanfan Liu; Mei Ma; Tong Yang; Yang Wang; Jinyu Su; Yanchao Zheng; Shan Gao; Qiang Xu; Lin Li; Chunquan Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-15       Impact factor: 6.055

4.  Leptin's activity on the hydroxyl radical: a possible link to the oxidative stress-related endothelial vasodilation in patients with obstructive sleep apnea.

Authors:  Madalina Macrea; Thomas Martin; Zhenquan Jia; Hara Misra
Journal:  Lung       Date:  2013-05-21       Impact factor: 2.584

5.  Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs.

Authors:  Mohamed Abu-Farha; Kazem Behbehani; Naser Elkum
Journal:  Cardiovasc Diabetol       Date:  2014-04-09       Impact factor: 9.951

6.  Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study).

Authors:  Razieh Hassannejad; Hamsa Sharrouf; Fahimeh Haghighatdoost; Ben Kirk; Farzad Amirabdollahian
Journal:  Nutrients       Date:  2021-06-30       Impact factor: 5.717

7.  Latent associations of low serum amylase with decreased plasma insulin levels and insulin resistance in asymptomatic middle-aged adults.

Authors:  Toshitaka Muneyuki; Kei Nakajima; Atsushi Aoki; Masashi Yoshida; Hiroshi Fuchigami; Hiromi Munakata; San-E Ishikawa; Hitoshi Sugawara; Masanobu Kawakami; Shin-Ichi Momomura; Masafumi Kakei
Journal:  Cardiovasc Diabetol       Date:  2012-06-29       Impact factor: 9.951

8.  Favorable Levels of All Major Cardiovascular Risk Factors at Younger Ages and High-Sensitivity C-Reactive Protein 39 Years Later -The Chicago Healthy Aging Study.

Authors:  Thanh-Huyen T Vu; Kiang Liu; Donald M Lloyd-Jones; Jeremiah Stamler; Amber Pirzada; Sanjiv J Shah; Daniel B Garside; Martha L Daviglus
Journal:  Prev Med Rep       Date:  2015

9.  Comparison of salivary and plasma adiponectin and leptin in patients with metabolic syndrome.

Authors:  Supanee Thanakun; Hisashi Watanabe; Sroisiri Thaweboon; Yuichi Izumi
Journal:  Diabetol Metab Syndr       Date:  2014-02-14       Impact factor: 3.320

Review 10.  Adipokines, metabolic syndrome and rheumatic diseases.

Authors:  Vanessa Abella; Morena Scotece; Javier Conde; Verónica López; Verónica Lazzaro; Jesús Pino; Juan J Gómez-Reino; Oreste Gualillo
Journal:  J Immunol Res       Date:  2014-02-26       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.